April 24, 2019 | Michael Easterling and Samantha Bonar
City of Hope’s bone marrow transplant program recently performed the procedure on its 15,000th patient, a remarkable milestone considering that the initiative started with just two physicians, three beds and guarded expectations in 1976.
Researchers detail new findings at 2019 AACR meeting
March 28, 2019 | Zen Vuong
City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
Minor diet changes can affect cancer risk, researcher finds
November 9, 2018 | City of Hope
On one hand, City of Hope's Rowan Chlebowski, M.D., Ph.D., is a medical oncologist and breast cancer expert. On the other, he’s a scientist specializing in observational studies who ranks among the most cited researchers in the world.
First-of-its-kind CAR T clinical trial enrolls HER2+ breast cancer patients with brain metastases
October 30, 2018 | City of Hope
City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.
A triple-negative breast cancer trial has its first success story
October 12, 2018 | Maxine Nunes
Linda Collins's outlook was bleak, thanks to her triple-negative breast cancer diagnosis, until City of Hope oncologist Yuan Yuan, M.D., Ph.D. helped develop a revolutionary new trial to help her.
Crime fighters fight breast cancer with the Pink Patch Project
October 11, 2018 | Maxine Nunes
San Bernardino District Attorney Child Abduction Unit investigative tech and City of Hope breast cancer survivor Michelle Faxon and her law enforcement colleagues are involved with the Pink Patch Project to raise funds for breast cancer research.
New hormone and immunotherapy trial for breast cancer patients
October 8, 2018 | City of Hope
This phase 2 trial studies the side effects and how well pembrolizumab and enobosarm work in treating patients with androgen receptor positive triple-negative breast cancer that has spread to other places in the body.
Patients over 60 needed for HER2-positive breast cancer study
October 7, 2018 | City of Hope
Researchers are actively recruiting for patients 60 years and older for a phase 2 trial studying the side effects of and how well neratinib works in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread from where it started to other places in the body.